EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Case report of durable responders to sintilimab plus second-line chemotherapy in relapsed/refractory angioimmunoblastic T-cell lymphoma

Wensi Zhao, Xiang Cheng

American Journal of Translational Research · 2026 · 18 (3) · 2483-2488

DOI: 10.62347/gkny9671 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Translational Research, 2026. Verfasst von Wensi Zhao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Renmin Hospital of Wuhan University Wuhan 430060, Hubei, China. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Angioimmunoblastic T-cell lymphomacase reportchemotherapyimmune checkpoint inhibitorprogression-free survivalsintilimab

Autor:innen und Institutionen

  • Department of Oncology, Renmin Hospital of Wuhan University Wuhan 430060, Hubei, China.

Zitieren

APA

Zhao, W., & Cheng, X. (2026). Case report of durable responders to sintilimab plus second-line chemotherapy in relapsed/refractory angioimmunoblastic T-cell lymphoma. American Journal of Translational Research, 18(3), 2483-2488. https://doi.org/10.62347/gkny9671

Vancouver

Zhao W, Cheng X. Case report of durable responders to sintilimab plus second-line chemotherapy in relapsed/refractory angioimmunoblastic T-cell lymphoma. American Journal of Translational Research. 2026;18(3):2483-2488. doi:10.62347/gkny9671

BibTeX
@article{Zhao2026,
  author = {Zhao, Wensi and Cheng, Xiang},
  title = {Case report of durable responders to sintilimab plus second-line chemotherapy in relapsed/refractory angioimmunoblastic T-cell lymphoma},
  journal = {American Journal of Translational Research},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {2483--2488},
  doi = {10.62347/gkny9671}
}
Kostenlos starten →